Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIT2: Ianalumab plus eltrombopag in primary immune thrombocytopenia after steroid failure
2024-512890-28-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in immune thrombocytopenia (ITP) (3 arms), sponsored by Novartis. Primary endpoint: Time to treatment failure. Planned start Aug 2024; status: authorised.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-512890-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512890-28-00.